Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models

被引:14
|
作者
Basheer, Loai [1 ]
Schultz, Keren [1 ]
Kerem, Zohar [1 ]
机构
[1] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
HERB-DRUG INTERACTION; P450-MEDIATED METABOLISM; STRUCTURAL BASIS; CYP3A4; RAT; MECHANISM; TRANSPORT; ENZYMES; LIVER; BIOAVAILABILITY;
D O I
10.1038/srep31557
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many dietary compounds, including resveratrol, are potent inhibitors of CYP3A4. Here we examined the potential to predict inhibition capacity of dietary polyphenolics using an in silico and in vitro approaches and synthetic model compounds. Mono, di, and tri-acetoxy resveratrol were synthesized, a cell line of human intestine origin and microsomes from rat liver served to determine their in vitro inhibition of CYP3A4, and compared to that of resveratrol. Docking simulation served to predict the affinity of the synthetic model compounds to the enzyme. Modelling of the enzyme's binding site revealed three types of interaction: hydrophobic, electrostatic and H-bonding. The simulation revealed that each of the examined acetylations of resveratrol led to the loss of important interactions of all types. Triacetoxy resveratrol was the weakest inhibitor in vitro despite being the more lipophilic and having the highest affinity for the binding site. The simulation demonstrated exclusion of all interactions between tri-acetoxy resveratrol and the heme due to distal binding, highlighting the complexity of the CYP3A4 binding site, which may allow simultaneous accommodation of two molecules. Finally, the use of computational modelling may serve as a quick predictive tool to identify potential harmful interactions between dietary compounds and prescribed drugs.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] EFFECT OF CANNABIDIOL (CBD) ON CYTOCHROME P450 3A IN THE MOUSE
    BORNHEIM, LM
    EVERHART, ET
    LI, J
    FASEB JOURNAL, 1993, 7 (03): : A265 - A265
  • [32] Estrogen regulation of the cytochrome P450 3A subfamily in humans
    Williams, ET
    Leyk, M
    Wrighton, SA
    Davies, PJA
    Loose, DS
    Shipley, GL
    Strobel, HW
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (02): : 728 - 735
  • [33] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    D A Flockhart
    J M Rae
    The Pharmacogenomics Journal, 2003, 3 : 3 - 5
  • [34] How important is intestinal cytochrome P450 3A metabolism?
    van Herwaarden, Antonius E.
    van Waterschoot, Robert A. B.
    Schinkel, Alfred H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (05) : 223 - 227
  • [35] Cytochrome P450 3A: Genetic polymorphisms and interethnic differences
    Krishna, DR
    Shekar, MS
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2005, 27 (08): : 559 - 567
  • [36] Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo
    Thapliyal, R
    Maru, GB
    FOOD AND CHEMICAL TOXICOLOGY, 2001, 39 (06) : 541 - 547
  • [37] Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast
    Shader, RI
    Granda, BW
    von Moltke, LL
    Giancarlo, GM
    Greenblatt, DJ
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1999, 20 (08) : 385 - 388
  • [38] Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity
    Hidaka, M
    Fujita, K
    Ogikubo, T
    Yamasaki, K
    Iwakiri, T
    Okumura, M
    Kodama, H
    Arimori, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (06) : 581 - 583
  • [39] Insights into oral bioavailability enhancement of therapeutic herbal constituents by cytochrome P450 3A inhibition
    Chen, Junmei
    Liu, Jinman
    Huang, Yueyue
    Li, Ruoyu
    Ma, Cuiru
    Zhang, Beiping
    Wu, Fanchang
    Yu, Wenqian
    Zuo, Xue
    Liang, Yong
    Wang, Qi
    DRUG METABOLISM REVIEWS, 2021, 53 (04) : 491 - 507
  • [40] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    Farid, N. A.
    Payne, C. D.
    Small, D. S.
    Winters, K. J.
    Ernest, C. S., II
    Brandt, J. T.
    Darstein, C.
    Jakubowski, J. A.
    Salazar, D. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 735 - 741